Botanix Pharmaceuticals gets approval for synthetic cannabidiol trial

Botanix Pharmaceuticals (ASX:BOT) has received approval to conduct the first clinical study of synthetic cannabidiol for acne using the company’s BTX 1503 product.

The approval was granted by the Human Research Ethics Committee (HREC) of the Queensland Institute for Medical Research.

Botanix’s shares were last trading 10% higher intra-day, at $0.064.

The recruitment of volunteers for the safety and pharmacokinetic studies will begin shortly in Queensland, and the data will be available in Q2 CY2017.

Botanix continues to rapidly advance in parallel preparation for the follow-on pilot study in acne patients, and will commence the study following review of the data from these first studies.

Importantly, these studies will be the first to be conducted anywhere in the world using synthetic cannabidiol for the treatment of a skin disease, with oversight from a regulator.

The approval to commence human studies comes less than nine months after Botanix’s listing on the

... read more at: